US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Carlsmed, Inc. (CARL): Peeking at the Prospectus of the Next Medical Tech IPO

Carlsmed, Inc. (CARL): MedTech Targeting the Spine Sets Terms for IPO

Carlsmed, Inc. (CARL): Spinal Fusion Surgery Focused Company Looking to Be Next MedTech IPO Winner

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Carlsmed, Inc. (CARL) priced a full-size deal of 6.7mm shares at $15.00 (midpoint of the range) and opened at $15.00.</li>
<li>There were concerns with the color coming from the book as the underwriters failed to provide price guidance to investors the day of pricing on the deal.</li>
<li>Given that the deal "broke" on day one, we believe investors "may" be turned off by the company in the short term.</li>
</ul>


Carlsmed, Inc. (CARL) priced a full-size deal of 6.7mm shares at $15.00 (midpoint of the range) and opened at $15.00.
There were concerns with the color coming from the book as the underwriters failed to provide price guidance to investors the day of pricing on the deal.
Given that the deal "broke" on day one, we believe investors "may" be turned off by the company in the short term.


Carlsmed Inc. (CARL): MedTech Makes Uninspiring Debut, Opens Flat and Trades Below Issue